Delforge, M., Terpos, E., Richardson, P. G., Shpilberg, O., Khuageva, N. K., Schlag, R., . . . San Miguel, J. F. (2011). Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. European journal of haematology, 86(5), . https://doi.org/10.1111/j.1600-0609.2011.01599.x
Chicago-Zitierstil (17. Ausg.)Delforge, Michel, et al. "Fewer Bone Disease Events, Improvement in Bone Remodeling, and Evidence of Bone Healing with Bortezomib Plus Melphalan-prednisone Vs. Melphalan-prednisone in the Phase III VISTA Trial in Multiple Myeloma." European Journal of Haematology 86, no. 5 (2011). https://doi.org/10.1111/j.1600-0609.2011.01599.x.
MLA-Zitierstil (9. Ausg.)Delforge, Michel, et al. "Fewer Bone Disease Events, Improvement in Bone Remodeling, and Evidence of Bone Healing with Bortezomib Plus Melphalan-prednisone Vs. Melphalan-prednisone in the Phase III VISTA Trial in Multiple Myeloma." European Journal of Haematology, vol. 86, no. 5, 2011, https://doi.org/10.1111/j.1600-0609.2011.01599.x.